The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)
oleh: Faith E. Davies, Ping Wu, Matthew Jenner, Muralikrishan Srikanth, Radovan Saso, Gareth J. Morgan
| Format: | Article |
|---|---|
| Diterbitkan: | Ferrata Storti Foundation 2007-08-01 |
Deskripsi
The combination of bortezomib (velcade), pulsed dexamethasone and weekly cyclophosphamide (CVD) in relapsed/refractory myeloma patients induces high overall (75%) and complete (31%) response rates compared to velcade/dexamethasone (overall 47%, CR 5%) and velcade alone (overall 27%, CR 0%). The toxicity profiles including thrombocytopenia, neutropenia, and neuropathy were comparable between the groups.